Companies › Astria Therapeutics
3 active drug programs in 4 registered trials: 2 Phase 1, 1 Phase 3, 1 Phase 2; Other, Immunology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| navenibart | – | Phase 3 | Hereditary Angioedema (HAE); Healthy Adult Participants | Dec 2026 |
| STAR-0215 | – | Phase 2 | Hereditary Angioedema | Mar 2031 |
| STAR-0310 | – | Phase 1 | Healthy Participants | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06782477 | STAR-0310 | Phase 1 | Healthy Participants | Other | Jan 2026 |
| NCT06842823 | navenibart | Phase 3 | Hereditary Angioedema (HAE) | Immunology | Dec 2026 |
| NCT07635095 | navenibart | Phase 1 | Healthy Adult Participants | Other | Dec 2026 |
| NCT06007677 | STAR-0215 | Phase 2 | Hereditary Angioedema | Immunology | Mar 2031 |
No annotated target.
–
Mirador Therapeutics Daewon Pharmaceutical Accro Bioscience (Suzhou) Clarent Biopharma Zhejiang Wenda Pharma Technology
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.